<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01122563</url>
  </required_header>
  <id_info>
    <org_study_id>EQL-CRU.005-2009</org_study_id>
    <nct_id>NCT01122563</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Response of Overactive Bladder Symptom Score (OABSS) to Treatment</brief_title>
  <acronym>RESORT-2</acronym>
  <official_title>Reproducibility Study of OABSS and Its Response to Treatment in Indonesia - Part 2: Responsiveness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Indonesia Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate change of overactive bladder symptom scores (OABSS) between, before
      and after solifenacin treatment to OAB subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OABSS</measure>
    <time_frame>Weeks 0, 4 and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Prostate Symptom Score (IPSS)</measure>
    <time_frame>Weeks 0, 4 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) Score</measure>
    <time_frame>Weeks 0, 4 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Bladder Condition (PPBC)</measure>
    <time_frame>Weeks 0, 4 and 12</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">55</enrollment>
  <condition>Overactive Bladder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Solifenacin</intervention_name>
    <description>oral</description>
    <other_name>Vesicare</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Symptomatic OAB patients having urgency episodes
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptoms OAB for 3 months or longer

          -  At least 3 urgency episode in last 3 days

          -  Symptoms of OAB as verified by the screening 3-day bladder diary, defined by:

               -  Number of micturition ≥8 times/day

               -  Number of urgency episodes in 3 days ≥3

        Exclusion Criteria:

          -  Significant stress incontinence or mixed stress/urge incontinence

          -  Subject with indwelling catheters or practicing intermittent self-catheterization

          -  Symptomatic urinary tract infection, chronic inflammation

          -  Diabetic neuropathy

          -  Subjects who are prohibited from taking solifenacin as contraindications

          -  Drug or non-drug treatment for OAB was started, quitted or changed in 4 weeks

          -  Participation in any clinical trial in 30 days except for Part-1 of RESORT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Indonesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bandung</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Surabaya</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2010</study_first_submitted>
  <study_first_submitted_qc>May 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2010</study_first_posted>
  <last_update_submitted>January 11, 2011</last_update_submitted>
  <last_update_submitted_qc>January 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2011</last_update_posted>
  <responsible_party>
    <name_title>Disclosure Director</name_title>
    <organization>Astellas Pharma, Inc</organization>
  </responsible_party>
  <keyword>OABSS</keyword>
  <keyword>IPSS</keyword>
  <keyword>PPBC</keyword>
  <keyword>3-day micturition diary</keyword>
  <keyword>Solifenacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Solifenacin Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

